These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26287854)

  • 41. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction.
    Toth PP
    Am J Cardiol; 2016 Sep; 118(6 Suppl):19A-32A. PubMed ID: 27620356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" What do we do for the very old?
    Goodwin JS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):593-594; author reply 602. PubMed ID: 15972606
    [No Abstract]   [Full Text] [Related]  

  • 44. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors.
    Klug EQ; Raal FJ
    S Afr Med J; 2020 Oct; 110(11):13126. PubMed ID: 33403972
    [No Abstract]   [Full Text] [Related]  

  • 47. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 48. Promising new therapies for the treatment of hypercholesterolemia.
    Valerio MG; Velayati A; Jain D; Aronow WS
    Expert Opin Biol Ther; 2016; 16(5):609-18. PubMed ID: 26822080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
    Pokrywka GS
    Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New and Future Parenteral Therapies for the Management of Lipid Disorders.
    Garcia R; Burkle J
    Arch Med Res; 2018 Nov; 49(8):538-547. PubMed ID: 30739730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
    Capriotti T
    Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
    [No Abstract]   [Full Text] [Related]  

  • 54. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Hyperlipidemia in seniors: too much, too little, too late?
    Hirth VA
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):595-7; author reply 602. PubMed ID: 15972608
    [No Abstract]   [Full Text] [Related]  

  • 55. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Preventive gerontology: edging ever closer to the "barrier to immortality".
    Hazzard WR
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):594-5; author reply 602. PubMed ID: 15972607
    [No Abstract]   [Full Text] [Related]  

  • 56. PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application.
    Lekuona I
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):996-998. PubMed ID: 30150140
    [No Abstract]   [Full Text] [Related]  

  • 57. Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management.
    Zárate A; Manuel-Apolinar L; Saucedo R; Hernández-Valencia M; Basurto L
    Arch Med Res; 2016 Oct; 47(7):491-495. PubMed ID: 28262189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 59. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.